Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.
Patients with cancer have an impaired T-cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy. L-arginine (L-Arg) is a conditionally essential amino acid that is fundamental for the function of T lymphocytes. Recent findings in tumor-bearing mice and cancer patients indicate that increased metabolism of L-Arg by myeloid derived suppressor cells (MDSCs) producing arginase I inhibits T-lymphocyte responses. Here we discuss some of the most recent concepts how MDSC expressing arginase I may regulate T-cell function in cancer and other chronic inflammatory diseases and suggest possible therapeutic interventions to overcome this inhibitory effect.
Rodríguez
Paulo C
PC
Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Ochoa
Augusto C
AC
D000818:Animals; D001119:Arginase / Q000276:immunology / Q000378:metabolism; D001120:Arginine / Q000276:immunology* / Q000378:metabolism; D017252:CD3 Complex / Q000276:immunology; D004790:Enzyme Induction; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D051379:Mice; D018448:Models, Immunological; D022423:Myeloid Cells / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D015398:Signal Transduction / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D019139:Tumor Escape
D017252:CD3 Complex; C121704:CD3 antigen, zeta chain; D001120:Arginine; D001119:Arginase